What Signos does

Signos is a digital health company headquartered in Burlingame, California, that operates an FDA-cleared, AI-powered metabolic health platform combining continuous glucose monitoring (CGM) with personalized coaching for sustainable weight management. The core product pairs Dexcom's Stelo 15-day biosensor, which delivers a glucose reading every five minutes via Bluetooth, with the Signos mobile app. The app applies machine learning to the user's glucose time-series plus logged meals, workouts, sleep, and stress data to predict individual glycemic responses, surface personal food triggers, recommend movement to blunt spikes, and assign daily and weekly metabolic scores. The company received the first FDA clearance for an OTC CGM specifically indicated for weight management in 2025.

Signos generates revenue through tiered direct-to-consumer subscriptions ($127-$225 per month depending on commitment length, hardware included), the Signos+ GLP-1 Bundle ($199/month, pairing CGM with clinician-prescribed GLP-1 medication via partner OpenLoop Health), enterprise contracts with self-insured employers (Google and Samsung are named customers), health plan partnerships (BCBS Alabama's 450 Ventures is an investor), and a referral channel through functional medicine practitioners. Pricing is multi-month commitment-driven with HSA/FSA eligibility and a 30-day results guarantee.

The company's strategic moat rests on regulatory first-mover status in the OTC weight-management CGM category, a proprietary data asset (the Signos Atlas covering 3.1M+ member meals and 179 foods), and a tightly aligned strategic investor syndicate led by Dexcom, Google Ventures, and Samsung NEXT. The platform integrates with Apple Health, Google Health Connect, smartwatches, and smart scales, and is supported by registered dietitian services through partner Berry Street. Signos was founded in 2018 and has raised approximately $57M across multiple venture rounds, most recently a $20M financing in May 2026 that coincided with an expanded commercial partnership placing Signos on Dexcom's Stelo.com DTC platform.

Name

Signos

Legal name

Signos Inc.

Website

https://signos.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Signos pairs an FDA-cleared continuous glucose monitor (Dexcom Stelo) with an AI-powered app to deliver personalized metabolic insights and coaching for weight management, sold via D2C subscriptions, enterprise employer benefits, and health plan partnerships.

Ownership category

akta.pro rank

Product category

Digital Metabolic Health Platform

akta.pro primary industry

Continuous Glucose Monitoring (CGM) Systems (HLAHAHAA)

akta.pro secondary industry

Blood Glucose Monitoring Devices (Consumer CGM & Smart Glucometers) (CRACAQAE)

Keywords

• Continuous glucose monitoring
• Metabolic health platform
• Weight management technology
• AI health insights
• Digital therapeutics

Headquarters

HQ city

Burlingame

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Software

Cost components

Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations

Revenue model

1. CGM Subscription Plans (Direct-to-Consumer): Monthly subscription model for FDA-cleared continuous glucose monitoring system. Plans include hardware (Dexcom Stelo sensors), AI-powered app access, metabolic insights, food logging, and behavior coaching. Three tiers with discounts for longer commitments: 1-month ($225), 3-month ($150/month), and 6-month ($127/month). Hardware included in membership.
2. Signos+ GLP-1 Bundle: Combined subscription offering pairing clinician-prescribed GLP-1 medication (compounded Tirzepatide and Semaglutide) with CGM monitoring and AI-powered app. Available at $199/month for 3 or 6-month programs. Revenue includes medication costs, CGM hardware, and clinical services through partner OpenLoop Health.
3. Enterprise Employer Plans: B2B subscription model for employers offering Signos as employee benefit. Organizations gain population-level analytics, real-time visibility into adoption and outcomes, and dashboard reporting. Positioned as alternative or complement to GLP-1 coverage to reduce specialty drug costs.
4. Health Plan Partnerships: B2B partnerships with health insurance carriers to offer Signos as an innovative benefit for member populations. Health plans deploy Signos as standalone metabolic health solution or complement to GLP-1 strategy.
5. Healthcare Partner Referrals: Partnership with functional medicine practitioners, longevity clinics, and performance coaching practices. Practitioners refer patients through streamlined portal with no EHR integration or prescription workflow required. Signos handles fulfillment, onboarding, and AI coaching.

Pricing tiers

Go-to-market motion3 records

Distribution channels6 records

Marketing channels8 records

Core offering

Signos sells an FDA-cleared, over-the-counter continuous glucose monitoring (CGM) weight management system that pairs a Dexcom Stelo biosensor with an AI-powered mobile app. Subscriptions deliver real-time glucose readings every 5 minutes and use proprietary machine learning to translate this data into personalized metabolic insights, predictive meal scoring, movement nudges, and behavior coaching. The platform also offers a Signos+ bundle combining clinician-prescribed GLP-1 medication with CGM monitoring, plus enterprise offerings for employers, health plans, and clinical partners.

Product overview

Signos is a real-time metabolic health platform that combines an FDA-cleared continuous glucose monitor (CGM) with an AI-powered mobile application to help users understand how their bodies respond to food, exercise, sleep, and stress for sustainable weight management. The core offering includes the Signos CGM Platform paired with the Dexcom Stelo biosensor, which delivers continuous glucose readings every 5 minutes. The platform offers tiered subscription plans ($127/month for 6-month, $150/month for 3-month, $225/month for 1-month) plus the Signos+ GLP-1 Bundle ($199/month) which combines GLP-1 medication prescriptions with the CGM system. Enterprise solutions include dedicated programs for employers, health plans, and health partners. The product ecosystem also includes the Signos Atlas, a proprietary research database of CGM-backed food responses, and integrates with Apple Health, Google Health Connect, smartwatches, and smart scales.

Differentiator

Problem solved

Functional benefit

Brands

• Signos+ GLP-1 Bundle: A program that pairs clinician-prescribed GLP-1 medication with the FDA-cleared CGM and app, allowing users to lose weight, understand why, and know how to keep it off for the same price as medication alone.

Products and services

• Signos CGM Platform
• Signos+ GLP-1 Bundle
• Signos App
• Signos Atlas
• Signos for Employers
• Signos for Health Plans
• Signos for Health Partners

Quantifiable outcome

• 86% of members report success in their first month
• +8 more outcomes

Named customers7 records

Segments6 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability5 records

Feature6 records

Partnerships

Three partnerships are on record, tiered core.

• DexcomcoreStrategic or Co-development Partner · 27 May 2026Strategic partnership where Dexcom provides CGM hardware (Stelo biosensor) and distribution through Stelo.com DTC platform. Signos is the exclusive AI-powered weight management platform integrated with Dexcom's OTC CGM. Partnership expanded May 2026 with $20M investment and commercial agreement making Signos available for purchase through Dexcom's website. Dexcom's Stelo platform extends beyond core diabetes market into weight loss and wellness segment.
• Berry Street (Nourish)coreImplementation/ SI/ Consulting PartnerPartnership with Berry Street (operating as Nourish) provides registered dietitian services to Signos members. 95% of members pay $0 for dietitian consultations. Signos locks in lower pricing for members. Independent registered dietitians provide nutritional guidance integrated with glucose data.
• OpenLoop HealthcoreImplementation/ SI/ Consulting PartnerOpenLoop Health provides licensed clinicians for GLP-1 prescriptions and medical services through Signos+ program. Independent network of U.S.-licensed clinicians reviews patient intake and determines GLP-1 treatment eligibility. Signos does not employ licensed healthcare professionals; OpenLoop clinicians provide all medical services.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Found: Subscription weight management service combining clinician-prescribed medication with behavioral coaching, overlapping with Signos+'s combined pharmaceutical + lifestyle approach.
• Calibrate: Metabolic health platform pairing GLP-1 medication with coaching and habit change; highly comparable to Signos+'s medication-plus-coaching positioning in the same weight management category.

Direct peers

• Levels Health: Direct-to-consumer metabolic health platform that pairs CGM data with an AI app to provide real-time food and lifestyle feedback, targeting weight loss, energy, and metabolic optimization — overlapping directly with Signos' consumer CGM + AI coaching model.
• Nutrisense: DTC subscription service that provides CGMs paired with personalized nutritionist coaching and an app for tracking glucose responses to food, directly competing with Signos on consumer CGM-based weight and metabolic health.
• Zoe: Personalized nutrition company using CGMs alongside gut microbiome and blood fat data to deliver individualized food scores, sharing Signos' core premise of CGMs as a consumer weight/metabolic health tool with AI-driven personalization.

Broad incumbents

• Dexcom (Stelo): CGM hardware manufacturer whose Stelo OTC biosensor is the device underpinning Signos; also a strategic investor. While currently a partner, Dexcom is both enabler and potential competitor via its own Stelo consumer platform and analytics.
• Abbott (Lingo): Abbott's Lingo consumer CGM and broader FreeStyle Libre biosensor portfolio target the same beyond-diabetes metabolic wellness segment as Signos, with significant hardware R&D and consumer marketing scale.
• Noom: Large-scale digital weight management platform combining psychology-based coaching with food logging; competes for the same consumer weight-loss wallet share, though without CGM hardware layer.
• Virta Health: Established telehealth provider for type 2 diabetes reversal and metabolic health using continuous care and monitoring; competes with Signos in the metabolic-condition and enterprise health-plan channels.
• Omada Health: Digital chronic care platform with employer/payer distribution for diabetes prevention, hypertension and weight management — competing with Signos for enterprise benefits and health plan budget alongside GLP-1 strategies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/signoshealth
• YouTubeyoutube.com/signoshealth
• Facebookfacebook.com/signoshealth
• LinkedInlinkedin.com/company/signoshealth
• Instagraminstagram.com/signoshealth
• TikToktiktok.com/@signoshealth
• Pinterestpinterest.com/signoshealth

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds4 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Signos